Navigation Links
Drug-target database lets researchers match old drugs to new uses

There are thousands of drugs that silence many thousands of cancer-causing genetic abnormalities. Some of these drugs are in use now, but many of these drugs are sitting on shelves or could be used beyond the disease for which they were originally approved. Repurposing these drugs depends on matching drugs to targets. A study recently published in the journal Bioinformatics describes a new database and pattern-matching algorithm that allows researchers to evaluate rational drugs and drug combinations, and also recommends a new drug combination to treat drug-resistant non-small cell lung cancer.

"Most cancers have more than one genetic alternation. And even genetically targeted drugs tend to affect more than only their stated target. And so the challenge is matching drugs with many effects to cancers with many causes in a way that best maps the drugs' effects onto the intended targets," says Aik Choon Tan, PhD, investigator at the University of Colorado Cancer Center and associate professor of Bioinformatics at the CU School of Medicine.

There are about 500 kinases in the human genome, each of which represents a potentially important drug target. Tan describes the database as a spreadsheet with 500 columns, each column representing a kinase. Heading each row is a drug and then in each column cell is that drug's activity against the kinase.

"Imagine you know a cancer is caused by five kinases acting in unison," Tan says. "Our approach would allow you to query the database for this pattern and discover the drug or combination of drugs that best match the genetic needs."

Because many of these drugs have already earned FDA approval for use in other diseases, the processes of repositioning these drugs for new diseases is much less involved and expensive than if drug developers had started fresh.

Tan and colleagues put the technique to use to recommend drugs that could turn off the kinases that non-small cell lung cancer uses to create resistance existing treatments. It's been an important question many lung cancers depend on over-activation of the gene EGFR, but then when EGFR inhibitors like gefitinib or erlotinib are used, the cancers tend to activate other "kinases" that allow the cancer to by-pass around this dependence. Tan and colleagues asked what are these kinases that allow lung cancer to evade gefitinib, and what other drug might turn them off.

The answer may be in the drug bosutinib, developed by Pfizer, which earned FDA approval in 2013 for the treatment of chronic myeloid leukemia. The drug out-competes the body's energy source, ATP, for space in kinases and so keeps them from being activated. And it turns out that bosutinib may inhibit the activity of exactly the kinases that EGFR-dependent lung cancers need to mutate around the challenge of EGFR inhibitors.

In tests on EGFR-dependent lung cancer cell lines, Tan and colleagues show that the drugs gefitinib and bosutinib "showed additive and synergistic effects."

In a mechanism that Tan hopes will become common, his group will now hand off this rational combination to other researchers at the CU Cancer Center and elsewhere who will move the drugs toward a human clinical trial.


Contact: Garth Sundem
University of Colorado Denver

Related medicine news :

1. Researchers create database to examine vast resources of health legacy foundations
2. Best Business Insurance Prices Now Generated for Companies Online Through New Database Tool
3. Loyola receives Innovation Award for clinical research database
4. Fitments Information and Specs Provider, SizeItUp, Adds Brand Alloy Technologies To Database
5. Database tracks toxic side effects of pharmaceuticals
6. BioPharm Systems to Host Webinar on Evaluating and Investigating Drug Safety Signals with Public Databases
7. Worlds largest disease database will use artificial intelligence to find new cancer treatments
8. Doctor Evidence Introduces New “Evidence Community” Approach to Therapeutic Area Database Development Inside Medical Manufacturers
9. Metro Detroit Foot Doctor Releases Foot Problem Database on New Website
10. Definitive Healthcare Expands Database Coverage With Detailed Research On Over 400+ Health Insurance Payors
11. Excellent Wheel Brand, Cabo is Now Added in SizeItUp Database.
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... recently awarded their highest five-star rating ... Millions of individuals in the United States and Canada wear eyeglasses. Once considered to ... correct vision and make a fashion statement. Even celebrities use glasses as a way ...
(Date:6/26/2016)... ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is ... a fitness app. The fitness app plans to fix the two major problems leading the ... one size fits all type program , They don’t eliminate all the reasons ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... NAMUR , Belgium , ...  (NYSE MKT: VNRX), today announced the appointment of ... Board of Directors as a Non-Executive Director, effective ... the Company,s Audit, Compensation and Nominations and Governance ... Board, Dr. Futcher will provide independent expertise and ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... date financial data derived from varied research sources to present ... impact on the market during the next five years, including ... sub markets, regional and country level analysis. The report provides ...
Breaking Medicine Technology: